Replimune Group Inc.

09/11/2024 | Press release | Distributed by Public on 09/11/2024 18:29

Replimune Presents Late Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti PD1 Failed Melanoma at the 39th Annual Meeting of the[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.